Newsroom | 216475 results

NEW YORK--(BUSINESS WIRE)--Blue Matter oggi ha annunciato il lancio della sua People and Organization Practice, una funzionalità dedicata progettata per aiutare le aziende nel settore delle scienze della vita a creare organizzazioni in grado di gestire le complessità, dalla trasformazione aziendale e integrazione M&A alla strategia dei talenti, all'apprendimento, alla ridefinizione della forza lavoro. Il lancio riflette una convinzione basilare: il settore biofarmaceutico non sta attraversa...

NEW YORK--(BUSINESS WIRE)--Blue Matter kondigde vandaag de lancering aan van haar People & Organization Practice, een specifieke capaciteit ontworpen om bedrijven gespecialiseerd in biowetenschappen te helpen organisaties tot stand te brengen die in alle complexiteit kunnen presteren - van bedrijfstransformatie en M&A-integratie tot talentstrategie, leren en omscholing van personeel. De lancering weerspiegelt een centrale overtuiging: de biofarma-industrie zit niet in een cyclisch neerw...

NEW YORK--(BUSINESS WIRE)--Blue Matter a annoncé aujourd'hui le lancement de sa pratique « People and organization », une expertise dédiée conçue pour accompagner les entreprises des sciences de la vie dans le développement d'organisations performantes face à un environnement complexe - de la transformation d'entreprise et l'intégration des fusions-acquisitions à la stratégie des talents, à la formation et à la refonte des effectifs. Ce lancement témoigne d'une conviction fondamentale : l'indus...

韓國仁川--(BUSINESS WIRE)--(美國商業資訊)-- Samsung Bioepis Co., Ltd. 今日宣佈，公司已與 Sandoz 簽訂一項全球授權、開發及商業化協議 (DCA)。該協議涵蓋最多五款由 Samsung Bioepis 正在研發的生物相似藥候選藥物，其中包括以 Entyvio1 (vedolizumab) 為參考藥物的候選藥物 SB36。協議的其他條款暫時保密。 根據協議條款，Samsung Bioepis 將負責生物相似藥的開發、主要市場的監管機構註冊以及生產工作；而 Sandoz 則負責在全球市場（中國內地、中國香港、中國台灣、中國澳門及韓國除外）進行商業化推廣。 「我們非常高興能與 Sandoz 擴展互惠的合作關係，並就多項處於早期開發階段的生物相似藥項目達成商業化協議。對於身患頑疾且缺乏合適治療的患者而言，此次協議在提升生物製劑可及性方面邁出了重要一步，」Samsung Bioepis 總裁兼行政總裁 Kyung-Ah Kim 表示，「Samsung Bioepis 將繼續加強研發管線，致力讓全球各地的患者和醫療體系受惠，以兌現我們對發展生物...

NEW YORK--(BUSINESS WIRE)--Blue Matter gab heute die Einführung seiner People and Organization Practice bekannt, eines spezialisierten Kompetenzbereichs, der Unternehmen aus der Life-Science-Branche dabei unterstützen soll, Organisationen aufzubauen, die auch unter komplexen Bedingungen leistungsfähig bleiben – von der Unternehmenstransformation und der Integration nach Fusionen und Übernahmen bis hin zu Talentstrategie, Lernen und Neugestaltung der Belegschaft. Die Einführung beruht auf einer...

NUEVA YORK--(BUSINESS WIRE)--Blue Matter anunció hoy el lanzamiento de su práctica de personas y organizaciones, una funcionalidad exclusiva que se diseñó para ayudar a que las empresas de ciencias biológicas construyan organizaciones que puedan sostener su rendimiento en contextos complejos, desde la transformación empresarial y la integración con fusiones y adquisiciones hasta el rediseño de la fuerza de trabajo, la estrategia de talentos y el aprendizaje. El lanzamiento refleja una convicció...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the U.S. Food and Drug Administration (FDA) approved an expanded label for BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) in dogs. The updated indication adds treatment and control of Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months...

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (“Guardian”) (NYSE: GRDN) today announced the launch of a proposed underwritten public offering (the “Offering”) of 5,000,000 shares of its Class A common stock, consisting of 3,980,000 shares being offered by certain selling stockholders and 1,020,000 newly issued shares being offered by Guardian as part of a non-dilutive “synthetic secondary” transaction, as described below. In addition, the selling stockholders intend to grant the un...

SAN MATEO, Calif.--(BUSINESS WIRE)--Franklin Templeton, a global investment leader and its specialist investment manager, Clarion Partners, today announced that Clarion Partners has acquired The Grand at Spokane, a newly delivered luxury senior living community and full-continuum senior care facility located in the Spokane, Washington area. The acquisition was made on behalf of one of Clarion’s commingled funds and underscores the firm’s continued focus on high-quality healthcare and specialize...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2025 financial results and provided a business update. “The launch of our second-generation Swoop® scanner, our Optive AI™ software, and the addition of a new market in the neurology office setting in...